# Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

> **NCT00387504** · PHASE1 · COMPLETED · sponsor: **California Cancer Consortium** · enrollment: 21 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** fenretinide
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00387504
- **Lead sponsor:** California Cancer Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2013-07
- **Final completion:** —
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2013-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387504, "Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00387504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*